Pullinger C R, Hennessy L K, Chatterton J E, Liu W, Love J A, Mendel C M, Frost P H, Malloy M J, Schumaker V N, Kane J P
Cardiovascular Research Institute, University of California, San Francisco 94143.
J Clin Invest. 1995 Mar;95(3):1225-34. doi: 10.1172/JCI117772.
Detection of new ligand-defective mutations of apolipoprotein B (apoB) will enable identification of sequences involved in binding to the LDL receptor. Genomic DNA from patients attending a lipid clinic was screened by single-strand conformation polymorphism analysis for novel mutations in the putative LDL receptor-binding domain of apoB-100. A 46-yr-old woman of Celtic and Native American ancestry with primary hypercholesterolemia (total cholesterol [TC] 343 mg/dl; LDL cholesterol [LDL-C] 241 mg/dl) and pronounced peripheral vascular disease was found to be heterozygous for a novel Arg3531-->Cys mutation, caused by a C-->T transition at nucleotide 10800. One unrelated 59-yr-old man of Italian ancestry was found with the same mutation after screening 1,560 individuals. He had coronary heart disease, a TC of 310 mg/dl, and an LDL-C of 212 mg/dl. A total of eight individuals were found with the defect in the families of the two patients. They had an age- and sex-adjusted TC of 240 +/- 14 mg/dl and LDL-C of 169 +/- 10 mg/dl. This compares with eight unaffected family members with age- and sex-adjusted TC of 185 +/- 12 mg/dl and LDL-C of 124 +/- 12 mg/dl. In a dual-label fibroblast binding assay, LDL from the eight subjects with the mutation had an affinity for the LDL receptor that was 63% that of control LDL. LDL from eight unaffected family members had an affinity of 91%. By way of comparison, LDL from six patients heterozygous for the Arg3500-->Gln mutation had an affinity of 36%. The percentage mass ratio of the defective Cys3531 LDL to normal LDL was 59:41, as determined using the mAb MB19 and dynamic laser light scattering. Thus, the defective LDL had accumulated in the plasma of these patients. Using this mass ratio, it was calculated that the defective Cys3531 LDL particles bound with 27% of normal affinity. Deduced haplotypes using 10 apoB gene markers showed the Arg3531-->Cys alleles to be different in the two kindreds and indicates that the mutations arose independently. The Arg3531-->Cys mutation is the second reported cause of familial ligand-defective apoB.
载脂蛋白B(apoB)新的配体缺陷突变的检测将有助于识别与低密度脂蛋白(LDL)受体结合相关的序列。通过单链构象多态性分析对脂质门诊患者的基因组DNA进行筛查,以寻找apoB - 100假定的LDL受体结合域中的新突变。一名46岁具有凯尔特和美洲原住民血统的女性,患有原发性高胆固醇血症(总胆固醇[TC] 343 mg/dl;低密度脂蛋白胆固醇[LDL-C] 241 mg/dl)且有明显的外周血管疾病,被发现为一种新的Arg3531→Cys突变的杂合子,该突变由核苷酸10800处的C→T转换引起。在对1560名个体进行筛查后,发现一名59岁具有意大利血统的无关男性也有相同突变。他患有冠心病,TC为310 mg/dl,LDL-C为212 mg/dl。在两名患者的家族中总共发现了8名有该缺陷的个体。他们年龄和性别调整后的TC为240±14 mg/dl,LDL-C为169±10 mg/dl。相比之下,8名未受影响的家庭成员年龄和性别调整后的TC为185±12 mg/dl,LDL-C为124±12 mg/dl。在双标记成纤维细胞结合试验中,8名有突变的受试者的LDL对LDL受体的亲和力是对照LDL的63%。8名未受影响家庭成员的LDL亲和力为91%。作为比较,6名Arg3500→Gln突变杂合子患者的LDL亲和力为36%。使用单克隆抗体MB19和动态激光散射测定,缺陷型Cys3531 LDL与正常LDL的质量百分比比值为59:41。因此5。因此,缺陷型LDL在这些患者的血浆中蓄积。利用该质量比值计算得出,缺陷型Cys3531 LDL颗粒的结合亲和力为正常亲和力的27%。使用10个apoB基因标记推导的单倍型显示,两个家族中的Arg3531→Cys等位基因不同,表明这些突变是独立发生的。Arg3531→Cys突变是家族性配体缺陷型apoB的第二个报道病因。